| Cite this article: |
| WANG Yuanyuan,JIANG Lingling,LI Shutong,KONG Liang,YAN Jie,LIU Zhen,XU Baoli.Prescription optimization and evaluation of in vitro targeting effects of liver cancer stem cell niche responsive multistep targeting liposomes[J].Journal Of Pharmaceutical Research,2024,43(10):937-942,947[Click to copy] |
|
| 摘要: |
| 目的 制备负载多柔比星(DOX)和XAV-939的肝癌干细胞niche响应型逐级靶向脂质体(CAP@CD133-D/X-Lip),并初步评价其体外靶向作用。方法采用薄膜分散-硫酸铵梯度法制备CAP@CD133-D/X-Lip。通过Box-Behnken设计-响应面法确定CAP@CD133-D/X-Lip的最优处方制备工艺;通过加入纤维细胞活化蛋白(FAP-a)与脂质体反应测定粒径变化考察CAP@CD133-D/X-Lip中两亲肽(CAP)的敏感性;通过细胞摄取实验考察不同制剂对肝癌干细胞(LCSCs)的体外靶向能力。结果最优处方工艺为EPC 44 mg、Chol 2 mg、XAV-939 0.156 mg、DOX 1.16 mg、DSPE-PEG2000 2 mg、DSPE-PEG2000-MAL 2 mg、DSPE-PEG2000-CAP-PEG2000-UAMC1110 2 mg,超声功率为500 W,总处方量为5 mL,两药平均包封率为79.79%±0.89%;加入重组FAP-α蛋白后CAP@CD133-D/X-Lip的平均粒径缩小至(95.56±2.32)nm,显示出CAP@CD133-D/X-Lip具有较好的微环境响应能力;细胞摄取实验显示,相比于CAP@CD133-D/X-Lip,CAP@CD133-D/X-Lip+FAP-α有着更强的摄取能力,说明其靶向LCSCs的能力明显增强。结论本研究成功制备了CAP响应型逐级靶向LCSCs的脂质体,且其具有良好的微环境响应与体外靶向能力。 |
| 关键词: 脂质体 多柔比星 响应面法 肝癌干细胞 |
| DOI:10.13506/j.cnki.jpr.2024.10.001 |
| 基金项目:国家自然科学基金项目(No.82204629);辽宁省科技厅博士启动基金项目(No.2022-BS-197);大连大学附属中山医院博士启动课题(No.DLDXZSYY-BK201903);大连大学学科交叉项目(No.DLUXK-2023-YB-006) |
|
Publication Date:October 30, 2024
|
|
| Prescription optimization and evaluation of in vitro targeting effects of liver cancer stem cell niche responsive multistep targeting liposomes |
| WANG Yuanyuan1,JIANG Lingling1,LI Shutong2,KONG Liang2,YAN Jie1,LIU Zhen1,XU Baoli1 |
| (1.Department of Pharmacy, Affiliated Zhongshan Hospital of Dalian University, Dalian 116001,China; 2.School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600,China) |
| Abstract: |
| Objective To prepare liver cancer stem cell niche responsive multistep targeting liposome loaded with doxorubicin (DOX) and XAV-939(CAP@CD133-D/X-Lip), and to evaluate its targeting effect in vitro. Methods Thin film dispersion-ammonium sulfate gradient method was used to prepare CAP@CD133-D/X-Lip. The optimal prescription and preparation process were optimized by Box-Behnken response surface method. The sensitivity of amphipathic peptides (CAP) in CAP@CD133-D/X-Lip was evaluated by determining the particle size changes of liposomes through adding fibroblast activation protein (FAP-a). The in vitro targeting ability of different formulations to liver cancer stem cells (LCSCs) was investigated by cell uptake assay. Results The optimal formulation process was EPC 44 mg, Chol 2 mg, XAV-939 0.156 mg, DOX 1.16 mg, DSPE-PEG2000 2 mg, DSPE-PEG2000-MAL 2 mg, DSPE-PEG2000-CAP-PEG2000-UAMC1110 2 mg, ultrasound power was 500 W, total prescription volume was 5 mL, and the average encapsulation efficiency of the two drugs was 79.79%±0.89%. The average particle size of CAP@CD133-D/X-Lip reduced to (95.56±2.32) nm after the addition of recombinant FAP-α protein, indicating that CAP@CD133-D/X-Lip had an excellent microenvironment response. The cell uptake experiment showed that CAP@CD133-D/X-Lip+FAP-α had a stronger uptake ability than CAP@CD133-D/X-Lip, indicating that its ability to target LCSCs was significantly enhanced. Conclusions CAP-responsive multistep targeting liposomes to LCSCs are successfully prepared, and they have good microenvironment response and in vitro targeting ability. |
| Key words: Liposomes Doxorubicin Response surface method Liver cancer stem cells |